drugset / Trial / NCT01215955

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

NCT01215955

Phase 4 Completed 1117 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants with type 2 diabetes mellitus not achieving adequate glycemic control on basal insulin.

Timeline

Start
2010-12
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic Subcutaneous
Background insulin glargine Protein / enzyme biologic Subcutaneous